Perioperative management of bariatric surgery patients: Focus on metabolic bone disease

**ABSTRACT**

Chronic vitamin D deficiency, inadequate calcium intake, and secondary hyperparathyroidism are common in obese individuals, placing them at risk for low bone mass and metabolic bone disease. After bariatric surgery, they are at even higher risk, owing to malabsorption and decreased oral intake. Meticulous preoperative screening, judicious use of vitamin and mineral supplements, addressing modifiable risk factors, and monitoring the absorption of key nutrients postoperatively are essential in preventing metabolic bone disease in bariatric surgery patients.

**KEY POINTS**

Metabolic bone disease in obese patients is multifactorial: causes include sequestration of vitamin D in the adipocytes, inadequate nutrition due to chronic dieting, and lack of physical activity.

Before bariatric surgery, one must look for and treat preexisting nutritional deficiencies.

In the immediate postoperative period, aggressive strategies (ie, giving multivitamins and minerals intravenously and orally) can prevent nutritional deficiencies and secondary bone disease.

Postoperatively, many bariatric patients require chewable or liquid supplements to facilitate adequate absorption.

Clinical suspicion, timely interventions, and lifelong monitoring can prevent metabolic bone disease in bariatric surgery patients.

---

A 56-YEAR-OLD WOMAN who underwent Roux-en-y bariatric surgery because of morbid obesity 6 years ago presents to her primary care physician with vague complaints of fatigue, myalgias, arthralgias, and weakness that have slowly been getting worse. Before surgery she weighed 340 pounds (154 kg), and in the first 2 years afterward she lost 160 pounds (72.5 kg). She is postmenopausal, has no history of fractures, nephrolithiasis, or thyroid disease, and does not smoke or consume alcohol. She gives herself monthly intramuscular vitamin B12 injections, and takes a multivitamin tablet, calcium carbonate 500 mg, and vitamin D 400 IU daily.

After her surgery she returned for her first two postoperative appointments, but because she was feeling well, was losing weight, and had returned to work full-time, she cancelled all subsequent appointments with the surgeon, bariatrician, and dietitian.

On physical examination, the patient’s weight is stable at 187 pounds (84.5 kg), her height is 165.1 cm, and her body mass index is 31. Her head, eyes, ears, nose, throat, heart, lungs, and abdomen are normal. Her upper legs are weak, requiring her to use her arms in rising from a chair, and she feels discomfort when the proximal muscles of her arms and legs are palpated. She has mild osteoarthritis of the hands and knees. Her neurologic examination is normal.

---

Dr. Richmond has disclosed that he has received honoraria from Procter and Gamble for teaching and speaking. Dr. Schauer has disclosed that he is a consultant for or on the scientific advisory boards of Bard-Davol, BaroSense, Baxter, Ethicon Endosurgery, Gore, and Stryker Endoscopy; is on the board of directors and is a partner in Remedy MD; and has received grant support from Invacare.
Pertinent laboratory data:
- Calcium 8.1 mg/dL (reference range 8.5–10.5)
- Albumin 3.7 g/dL (3.4–4.7)
- Magnesium 1.9 mg/dL (1.7–2.6)
- Phosphorus 2.7 mg/dL (2.4–4.5)
- Alkaline phosphatase 240 U/L (40–150)
- Intact parathyroid hormone 215 pg/mL (10–60)
- 25-hydroxyvitamin D < 7.0 ng/mL (31–80)
- 24-hour urine volume 2,310 mL
- Urine creatinine normal
- Urine calcium 25.4 mg/24 hours (100–300).

Dual-energy x-ray absorptiometry (DXA) data, lumbar spine:
- Bone mineral density 0.933 g/cm²
- T score –2.0
- Z score –0.8.

Left total hip:
- Bone mineral density 0.628 g/cm²
- T score –2.6
- Z score –2.4.

**METABOLIC BONE DISEASE: A CASE IN POINT**

This is a classic presentation of metabolic bone disease in a bariatric surgery patient lost to follow-up. Many patients have nonspecific and vague symptoms for many months or years that are often incorrectly diagnosed as fibromyalgia, rheumatoid arthritis, polyarthritis rheumatica, Paget disease, or depression. They typically have low serum and urine calcium levels, very low or undetectable 25-hydroxyvitamin D levels, high alkaline phosphatase levels, secondary hyperparathyroidism, and a clinical picture consistent with both osteomalacia and osteoporosis.1

This case underscores the importance of monitoring nutrients and biochemical markers at baseline and on an ongoing basis to detect early indicators of malabsorption and ultimately prevent the development of metabolic bone disease and fragility fracture, with its risks of disability and even death. It also illustrates the essential role that primary care physicians play in the continuing care of these patients.

**THE OBESITY-BONE CONNECTION**

Although we used to think that morbid obesity protected against metabolic bone disease, in fact, vitamin D and calcium deficiencies and elevated parathyroid hormone (PTH) levels are common in extremely obese people, placing them at risk of low bone mass. More than 60% of candidates for weight-loss surgery are deficient in vitamin D, and 25% to 48% have elevated PTH levels.

And that is before bariatric surgery: afterward, severely restricted oral intake and significant weight loss, coupled with a procedure that bypasses the major site of calcium absorption, place many patients at extremely high risk.

After combination restrictive and malabsorptive procedures (eg, the popular Roux-en-y procedure, in which the stomach is reduced in size—"restricted"—and the proximal duodenum is bypassed so that less food is absorbed), as patients lose weight their PTH levels rise and 25-hydroxyvitamin D levels decrease, although corrected calcium levels usually remain within normal limits. Secondary hyperparathyroidism has been documented as soon as 8 weeks after bariatric surgery, and osteomalacia after gastric bypass surgery is not uncommon.

Exclusively restrictive procedures such as gastric banding, formerly presumed not to alter bone metabolism, now also appear to place patients at risk of metabolic bone disease due to inadequate intake of calcium and vitamin D in the immediate postoperative period.

Numerous reported cases further illustrate the ever-present risk of metabolic bone disease in this population if adequate supplementation of calcium and vitamin D is not given. In these cases, significant bone disease occurred from 8 weeks to 32 years after bariatric surgery, often with devastating consequences.

**Voluntary weight loss, Involuntary bone loss**

When overweight or obese people lose weight—whether by dieting or by bariatric surgery—they also lose bone: a voluntary loss of approximately 10% of body weight results in a loss of 1% to 2% of bone at all sites. This loss appears to vary among populations: pre-
menopausal women younger than 45 years may be able to lose a moderate amount of weight without a significant increase in fracture risk, while a study of overweight men found that a 7% weight loss resulted in a 1% bone loss.\(^{15}\)

The percentage of bone lost correlates strongly with how fast the weight is lost. A recent study found that losing 0.7 kg/week was more detrimental to bone than a slower loss of 0.3 kg/week, due to the activation of the calcium-PTH axis.\(^{16}\)

After bariatric surgery, many patients rapidly lose 50 kg—some even lose 100 kg or more. This rapid weight loss, combined with severely restricted oral intake, decreased calcium absorption, and vitamin D deficiency places these patients at extremely high risk of rapidly developing metabolic bone disease.\(^3\,\(^8\,\(^9\)\)

In one large study, metabolic bone disease developed in more than 70% of patients who underwent a malabsorptive procedure, while in a second study, markers of bone resorption were elevated as soon as 8 weeks after bariatric surgery, regardless of whether the patient underwent a malabsorptive or restrictive bariatric procedure.\(^{13}\) Yet another study found that 48% of patients had a statistically signifi-

---

**TABLE 1**

Essential nutrients for preventing and treating metabolic bone disease after bariatric surgery

<table>
<thead>
<tr>
<th>Nutrient</th>
<th>Requirement</th>
<th>Sources</th>
<th>Additional Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein</td>
<td>1.0–1.5 g/kg body weight daily</td>
<td>Protein-rich foods</td>
<td>Recommended dietary allowance for obese patients: use adjusted body weight when calculating needs</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>800–1,000 IU</td>
<td>Casual sunlight exposure is the best source in warmer climates</td>
<td>It is difficult to obtain adequate vitamin D from dietary sources alone</td>
</tr>
<tr>
<td>Calcium</td>
<td>1,000 mg; ages 51 and up, 1,200 mg</td>
<td>Excellent food sources include dairy products</td>
<td>A chewable or liquid supplement may be easier to take and better absorbed</td>
</tr>
<tr>
<td>Vitamin B12</td>
<td>2.4 µg/day</td>
<td>Bariatric surgery patients should take a multivitamin that contains at least the RDA for B12</td>
<td>Postbariatric surgery patients should take a multivitamin that contains at least the RDA for B12</td>
</tr>
<tr>
<td>Magnesium</td>
<td>420 mg/day</td>
<td>Excellent food sources include legumes</td>
<td>A diet without legumes will tend to fall short of the magnesium recommended daily allowance; a multivitamin that contains magnesium until they can consume sufficient amounts of magnesium-rich foods</td>
</tr>
</tbody>
</table>

---

\(^{a}\)If the actual body weight is more than 125% of the ideal body weight, calculate the adjusted body weight:

\[
\text{adjusted body weight} = \left( \text{actual body weight} - \text{ideal body weight} \right) \times 0.25 + \text{ideal body weight}
\]
ESSENTIAL NUTRIENTS FOR BONE HEALTH

A number of nutrients are essential for bone health; we will limit our discussion to the major ones directly affected by obesity and bariatric surgery. Other nutrients often affected by obesity and bariatric surgery will be discussed in a subsequent article.

Protein
Dietary protein is needed to maintain bone structure, and although there is a link between high protein intake, calciuria, and fracture risk, the potentially harmful effects appear to be ameliorated when high protein intake is coupled with adequate calcium. This fact is of particular importance after bariatric surgery because once the patient can consume enough fluids to maintain hemodynamic stability, he or she is given a relatively high-protein diet to prevent protein malnutrition. Inadequate protein intake also has a detrimental effect on bone; therefore, it is essential to assess postoperative protein intake. Rizzoli and Bonjour noted that markers of bone turnover were higher with a low-protein diet (0.7 g protein per kg body weight) than with a diet containing 2.1 g protein per kg. In two trials examining graded levels of protein ingestion (0.7, 0.8, 0.9, and 1.0 g protein per kg body weight), decreased calcium absorption and an acute rise in PTH were noted by day 4 of the 0.7- and 0.8-g/kg diets but not during the 0.9- or 1.0-g/kg diets. And a systematic review of protein and bone health concluded that diets containing 1.0 to 1.5 g protein/kg are best for bone health. This is particularly worrisome, since the current recommended dietary allowance for protein is only 0.8 g/kg, which may be insufficient to promote calcium homeostasis.

Vitamin D
Vitamin D is essential for calcium absorption, stimulation of osteoblast activity, and normal bone mineralization throughout the life span. Dietary vitamin D is mainly absorbed by passive diffusion in the proximal and mid small intestine in a process that is highly dependent on bile salts. Dietary sources of vitamin D are clinically important because exposure to ultraviolet B radiation is often insufficient, especially in northern latitudes. Up to 84% of morbidly obese patients have vitamin D deficiency. The mechanism of vitamin D deficiency and secondary hyperparathyroidism in the morbidly obese remains unclear, although one study concluded they were likely due to sequestration of vitamin D in adipose tissue and subsequent limited bioavailability.

Correction of vitamin D deficiency requires more than just an over-the-counter multivitamin, but standard multivitamins also contain vitamin A, so taking more than one tablet a day increases the risk of vitamin A excess. Repletion can often be safely achieved orally by giving 50,000 IU of vitamin D weekly for 8 weeks, followed by a maintenance dose of one 50,000 IU tablet every 2 weeks. If a repeat serum level shows suboptimal repletion (less than 32 ng/mL), an additional 8-week course is recommended. For patients who cannot tolerate or adequately absorb oral supplements, exposure to sunlight is still the best source of vitamin D and is an effective alternative.

Calcium
Dietary calcium deficiency is a well-established risk factor for osteoporosis and fragility fractures. Therefore, supplemental calcium should be prescribed for patients who do not meet their defined need. A normal serum calcium level does not imply adequate calcium intake or absorption. Calcium homeostasis is tightly regulated and is maintained by a combination of gut absorption, bone resorption, and renal reabsorption. If dietary intake is inadequate, calcium is resorbed from the bone. The duodenum is the major site of active calcium uptake, while the rest of the small intestine and the colon appear to absorb some calcium passively. When the physiologic need for calcium is increased, active transport appears to take place throughout the duodenum, the ileum, and, to a lesser degree, the jejunum and the colon.

In the normal gastrointestinal tract, 20%
to 60% of dietary calcium is absorbed.\textsuperscript{36–38} Patients who have lost absorptive surface area (eg, after Roux-en-y bariatric surgery) need to have their calcium intake optimized. However, optimal dosing based on the type of surgical procedure is currently undefined.

Judicious monitoring for compliance and adequate absorption is recommended. Some patients will stop taking their calcium supplement due to gastrointestinal side effects such as gas, bloating, or constipation. And for some patients, a standard calcium supplement may be insufficient to promote adequate calcium absorption. Measuring urinary calcium in a 24-hour sample can help in assessing the adequacy of calcium intake: abnormally low urine calcium in the presence of normal renal function suggests inadequate absorption. For patients reporting gastrointestinal side effects or those with a history of calcium oxalate renal stones, calcium citrate supplements are better tolerated, alter urine acidity, and often prevent further stone formation.

\textbf{Vitamin B\textsubscript{12} (cobalamin)}

Vitamin B\textsubscript{12} deficiency is associated with increased fracture risk, and it may be an important modifiable risk factor for osteoporosis.\textsuperscript{39–41} After surgery, malabsorption of vitamin B\textsubscript{12} is commonly the result of altered gut function in the gastric pouch or sleeve, but malabsorption also occurs when more than 60 to 100 cm of terminal ileum has been bypassed.\textsuperscript{42} Vitamin B\textsubscript{12} supplementation is recommended for all patients after bariatric surgery, because deficiency is common.\textsuperscript{42} Patients with relatively mild malabsorption can maintain their B\textsubscript{12} level by taking 350 µg orally; however, many patients require lifelong subcutaneous injections.\textsuperscript{7,39,42–45}

\textbf{Magnesium}

Magnesium appears to affect bone remodeling and strength, to have a positive association with hip bone mineral density, and to play an important role in calcium and bone metabolism. Magnesium is absorbed in the distal small intestine by carrier-mediated and paracellular routes.\textsuperscript{46} When the distal small intestine is bypassed, magnesium deficiency occurs as a result of reduced absorption and chelation with unabsorbed fatty acids in the bowel lumen.\textsuperscript{42} Chronic hypomagnesemia impairs PTH secretion, resulting in altered calcium metabolism, hypocalcemia, and vitamin D abnormalities, further decreasing jejunal magnesium absorption.\textsuperscript{26,42,47}

Few well-designed studies have investigated the effect of magnesium intake on bone health, and although there is evidence that postmenopausal women may benefit from magnesium supplementation, studies of magnesium supplementation after bariatric surgery are lacking.\textsuperscript{47,48}

A prevailing misconception promoted by manufacturers of calcium-magnesium supplements and others is that magnesium is necessary for calcium absorption and efficacy. In fact, magnesium deficiency typically must be severe to impair calcium absorption. With usual dietary intake of magnesium and normal serum magnesium levels, no such relationship exists.\textsuperscript{49–53}

\textbf{THE ROLE OF DXA IN THE CARE OF THE BARIATRIC SURGERY PATIENT}

DXA is the gold standard for measuring bone density. The results are reported as a T score and as a Z score.

The T score is the bone density in an area of interest expressed in standard deviations from the mean value of a reference database of young adults. The World Health Organization defines normal as a T score greater than or equal to –1, low bone mass (previously called osteopenia) as a score between –1 and –2.5, and osteoporosis as a score of less than or equal to –2.5. (If a fragility fracture has occurred, “established” or “severe” osteoporosis is present.) Of note: these criteria only apply to DXA of the posterior-anterior spine, femoral neck, and the proximal (33%) radius in postmenopausal women and men over the age of 50 years.\textsuperscript{54,55} The International Society of Clinical Densitometry has extended the criteria to include total hip measurements.\textsuperscript{56}

The Z score should be used instead of the T score for premenopausal women and men younger than 50 years.\textsuperscript{56} The Z score is the patient’s bone mineral density expressed in standard deviations from the mean in a refer-
ence population matched for sex and age. A Z score greater than –2.0 is “within the expected range for age,” and –2.0 or lower is “below the expected range for age.” There are separate guidelines for DXA reporting in the diagnosis of metabolic bone disease in people younger than 20 years, and this topic is beyond the scope of this article.

If bone loss is exclusively due to the normal process of aging, the Z score will be near zero. However, if the Z score is less than –1.5, secondary causes of bone disease should be considered. All patients with Z scores lower than –2.0 should be further evaluated, and therapy should be based on the results of that evaluation (TABLE 2).34,56,57

Who should undergo DXA?
According to the International Society of Clinical Densitometry, bone density testing is indicated in the general population in women 65 years of age and older, postmenopausal women younger than 65 with risk factors, men 70 and older, adults with fragility fractures, adults taking a medication or having a disease or condition associated with low bone mass or bone loss, any patient being treated for low bone mass (to monitor the treatment effect), and any person in whom evidence of bone loss would affect treatment decisions.58

The National Osteoporosis Foundation recommends initiating therapy to reduce fracture risk in postmenopausal women with a central DXA T score below –2 in the absence of risk factors, and in women with T scores below –1.5 if one or more risk factors is present.34 Therefore, in view of the known risks, the likely need for interventions before surgery, and the ability to prevent the illness and death associated with metabolic bone disease, we recommend that all bariatric surgery patients undergo DXA at baseline as part of the preoperative evaluation.

Improvements in DXA technology
Newer DXA machines can accommodate patients weighing up to 450 pounds (the limit with older machines was 275 pounds for central measurements). In addition to measuring bone density, they also can map the distribution of fat in the body—patients with an android (apple-shaped) distribution are at higher risk of cardiovascular disease than those with a gynecoid (pear-shaped) distribution.59–63 For those patients who cannot be accommodated on a DXA table, DXA of the forearm can be used to assess bone density and fracture risk.

How often should DXA be repeated?
The estimated monitoring time interval is derived from the statistically defined least significant change divided by the anticipated change in bone density over time.64 When estimating the monitoring time interval for changes in body composition, the rate of weight loss and the psychological impact on the patient must be taken into consideration.

<table>
<thead>
<tr>
<th>TABLE 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Risk factors for metabolic bone disease</strong></td>
</tr>
<tr>
<td><strong>Bariatric surgery</strong></td>
</tr>
<tr>
<td><strong>Family history</strong></td>
</tr>
<tr>
<td>First-degree relative with fragility fracture</td>
</tr>
<tr>
<td><strong>Medical history</strong></td>
</tr>
<tr>
<td>Age &gt; 65 (women) or &gt; 70 (men)</td>
</tr>
<tr>
<td>Fracture history</td>
</tr>
<tr>
<td>Postmenopausal status</td>
</tr>
<tr>
<td>Early estrogen deficiency (&lt; 45 years of age)</td>
</tr>
<tr>
<td>Hypogonadism</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>Type 1 diabetes mellitus</td>
</tr>
<tr>
<td>Significant weight loss</td>
</tr>
<tr>
<td><strong>Medications</strong> (current or previous)</td>
</tr>
<tr>
<td>Antacids containing aluminum</td>
</tr>
<tr>
<td>Anticonvulsants (phenobarbital, phenytoin)</td>
</tr>
<tr>
<td>Cholestyramine</td>
</tr>
<tr>
<td>Gonadotropin-releasing hormone</td>
</tr>
<tr>
<td>Glucocorticoids (oral, used for &gt; 3 months or in multiple courses)</td>
</tr>
<tr>
<td>Heparin (long-term use)</td>
</tr>
<tr>
<td>Lithium</td>
</tr>
<tr>
<td>Methotrexate</td>
</tr>
<tr>
<td>Thyroid hormones (in excess)</td>
</tr>
<tr>
<td><strong>Morbid obesity</strong></td>
</tr>
<tr>
<td><strong>Social or lifestyle factors</strong></td>
</tr>
<tr>
<td>Alcohol use (&gt; 2 drinks daily)</td>
</tr>
<tr>
<td>Cigarette smoking</td>
</tr>
<tr>
<td>Eating disorder</td>
</tr>
<tr>
<td>Little or no physical activity</td>
</tr>
<tr>
<td>Low calcium intake (lifelong)</td>
</tr>
<tr>
<td>Poor dietary habits or chronic dieting</td>
</tr>
</tbody>
</table>
**Preventing and treating metabolic bone disease in bariatric surgery patients: Our recommendations**

**Preoperative evaluation**
Dual-energy x-ray absorptiometry (DXA)
Serum levels of: albumin, calcium, magnesium, phosphorus, alkaline phosphatase, folate, vitamin B₁₂, thyroid-stimulating hormone, 25-hydroxyvitamin D, intact parathyroid hormone

**Preoperative interventions**
Give prophylactic doses (appropriate to the patient’s age and sex) of multivitamins with minerals and of calcium and vitamin D
Give pharmacologic doses of vitamins, minerals, or both, if deficient

**Immediate postoperative period**
Intravenous multivitamin with minerals in the first liter of intravenous fluids daily × 3 days or until able to take oral supplements
Prescribe chewable or liquid form of multivitamin with minerals appropriate to the patient’s age and sex, and 1,800 mg calcium with 800–1,000 IU vitamin D

**Follow-up postoperative visits at 4 weeks; 3, 6, and 12 months; then annually**
Repeat preoperative laboratory tests
Reinforce compliance with prescribed supplements
Give pharmacologic-dose vitamin and/or mineral replacement if deficient or if malabsorption is evident
DXA: as recommended based on examination findings and the patient’s risk-factor profile

**INTERVENTIONS BASED ON DXA**

<table>
<thead>
<tr>
<th>T score</th>
<th>Normal bone density</th>
<th>Osteopenia (–1.0 to –2.5)</th>
<th>Osteoporosis (≤ –2.5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ –1.0</td>
<td>Counsel all patients on risk factor reduction including: Adequate consumption of calcium and vitamin D Regular weight-bearing and muscle-strengthening exercise Smoking cessation Limiting alcohol intake to 2 drinks daily Discontinue or substitute high-risk medications when clinically appropriate Initiate therapy for patients on long-term steroids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>–1.0 to –2.5</td>
<td>Counsel the patient on risk factor reduction Start therapy for women with one or more risk factors and a T score below –1.5 Start therapy for women with T scores below –2.0 Start therapy for any patient with a history of fragility fracture Start therapy for patients on long-term corticosteroid therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ –2.5</td>
<td>Counsel the patient on risk factor reduction Start therapy Schedule routine follow-up appointments to assess compliance and effectiveness of prescribed interventions Requires lifelong management</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*a World Health Organization definitions based on bone mass measurement at the spine, hip, and wrist in white, postmenopausal women. T scores are to be used to assist the clinician in determining the diagnosis and appropriate treatment options and can be misleading in younger women, men, and nonwhites.*
In general, DXA testing more frequently than every 2 years remains controversial unless one is initiating, monitoring, or changing therapy or monitoring conditions associated with rapid bone loss such as glucocorticoid therapy. In the bariatric surgery population, however, there is convincing evidence that significant changes may be detected after 12 months that would influence clinical decisions, particularly in the year immediately after surgery.8,9,13,21,27,65

Anabolic and antiresorptive bone drugs
Prescribed medications for the prevention and treatment of osteoporosis should also be an integral part of the treatment plan for at-risk morbidly obese patients. But the decision to prescribe an antiresorptive or bone-forming medication must take into consideration the patient’s risk-benefit profile, including the likelihood of gastrointestinal side effects and his or her ability and willingness to follow specific dosing instructions. Intravenous preparations are now available for patients who cannot absorb or tolerate oral antiresorptive medications. However, specific recommendations about the use of anabolic or antiresorptive bone medications in perioperative bariatric patients have yet to be elucidated.

**RECOMMENDATIONS**

Although a variety of recommendations have been published, there are no established guidelines for perioperative screening, risk stratification, or management of metabolic bone disease in bariatric surgery patients.7,44,65-67 And the literature remains inconclusive on key issues such as when to start supplements, which biochemical indices should be checked before surgery, whether baseline and annual DXA should be done, and whether antiresorptive agents such as bisphosphonates should be used prophylactically during rapid weight loss.

However, numerous studies and case reports cited here and elsewhere further underscore the ever-present risk of metabolic bone disease in this patient population, and the need for meticulous perioperative and long-term monitoring.44,65-67

Interventions should be individualized: we need to carefully consider the modifiable risk factors, the severity of disease, and the patient’s ability and willingness to participate in his or her care. Modifiable risk factors for progression of bone disease must be addressed in all patients at risk. It is also important to identify patients at high risk for falls due to poor visual acuity, frailty, neuropathy, or dementia and to implement risk management strategies to the degree possible.34

With these caveats in mind, we offer our recommendations (TABLE 3).

**Preoperative assessment**

We recommend obtaining baseline biochemical indices, including albumin, 25-hydroxyvitamin D, calcium, magnesium, phosphorus, alkaline phosphatase, folate, vitamin B12, thyroid-stimulating hormone, and PTH levels, and DXA in all bariatric surgery candidates. These indices should be used to assess for primary and secondary metabolic bone disease, to enable prompt presurgical interventions, and to guide the clinician in selecting appropriate postoperative interventions and surveillance.

We recommend starting a multivitamin with minerals at the first preoperative visit. A calcium supplement that provides calcium and vitamin D appropriate to the patient’s age and sex is also recommended until surgery. After surgery, and while rapid weight loss is occurring, a minimum of 1,800 mg of calcium and 800 to 1,000 IU of vitamin D is recommended, keeping in mind that the required level of supplemental vitamin D during periods of rapid weight loss remains unclear.68,69

However, before prescribing supplementation, one should thoroughly review the patient’s nutrition history, including the use of homeopathic medications, herbal preparations, and supplements. Many over-the-counter and over-the-Internet supplements are touted as being good for bone health, and some may indeed be beneficial, but others can be detrimental and need to be discontinued.27,47 Furthermore, in a patient with a severely restricted stomach capacity, it is important to ensure that less efficacious supplements do not compromise the intake of essential fluids, protein, and prescribed medications.
Immediate postoperative period
Hospitalization and surgery result in nutrient deficiencies. In bariatric surgery patients, particularly those who have preoperative nutritional deficiencies, repletion in the immediate postoperative period is believed to be of benefit. Therefore, in the immediate postoperative period we recommend infusing a standard-dose multivitamin with minerals daily along with adequate intravenous hydration until the patient can resume oral feeding. Once the patient can tolerate liquids, presurgical supplementation needs to be resumed, preferably in a liquid or chewable form to facilitate tolerance and absorption.

Short-term and long-term follow-up
Follow-up visits with a bariatric specialist should start 4 weeks after surgery and should be repeated every 3 to 4 months for the first year. If the patient continues to do well, annual visits may be sufficient thereafter. Compliance with supplements should be checked as indicated, as should nutritional indices. DXA should be repeated every 1 to 2 years, depending on the patient’s risk profile.

WHAT SHOULD BE DONE FOR OUR PATIENT?
Initial treatment for the patient described at the beginning of this article should include vitamin D repletion with cholecalciferol 50,000 IU, calcium supplements of at least 1,200 mg daily, and addressing of modifiable risk factors for fracture, including the risk of falling due to her proximal weakness. Her laboratory studies should be repeated in 6 to 12 weeks, with calcium and vitamin D supplement dosages adjusted on the basis of her response. Once the serum calcium level has normalized, we would consider the use of a bisphosphonate. DXA should be repeated in 1 to 2 years to monitor the effectiveness of the prescribed interventions.

REFERENCES
25. Giannini S, Nobile M, Sartori L, et al. Acute effects of moderate...


